Navigation Links
GeoPharma Announces Third Quarter Conference Call
Date:1/31/2008

LARGO, Fla., Jan. 31 /PRNewswire-FirstCall/ -- GeoPharma, Inc. (Nasdaq: GORX) announced today that it will host a conference call to discuss the results of its third fiscal quarter ended December 31, 2007 on Thursday, February 14, 2008 at 11:30 a.m. (ET) with CEO, Mihir Taneja and VP/CFO, Carol Dore-Falcone. Participants may pre-register for the conference call by utilizing the following URL, http://www.theconferencingservice.com/prereg/key.process?key=PVYY97BW8 thus avoiding operator assistance hold time and ensuring a spot in the queue. Participants may also dial in to register the day of the conference call 5 minutes before, or 11:25 a.m. The dial in number for participants is 1-888-286-8010, pass code 78555682. The Company will release the Company's operating results before trading the day of the call. Conference call replay will be available by dialing 1-888-286-8010 pass code 37538422 on February 14, 2008 at 1:30 p.m. through February 21, 2008.

GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a diversified business model participating in 3 main market segments: Specialty Pharma, Manufacturing, and Distribution. The Specialty Pharma division specializes in the formulation of generic drugs for human and veterinary usage and the development of medical devices used by oncologists and other medical professionals. The Manufacturing and Distribution divisions, manufacture, package, and distribute generic drugs, nutraceuticals, cosmetics, and functional food products for companies worldwide.

GeoPharma's growth strategy is to capitalize on its research and manufacturing expertise to develop medical devices and high margin generic drug products for niche markets with high barriers to entry. GeoPharma's competitive advantage in these areas is in its ability to navigate the challenges that such market pursuits present effectively.

Curr
'/>"/>

SOURCE GeoPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...v.25/PRNewswire/--Reportlinker.comannouncesthatane..., BrazilBioethanolMarketAnalysisandForecaststo2...razil-Bioethanol-Market-Analysis-and-Forecasts-to-...Forecaststo2013 ,, Summary ,, Thereportpro...anolmarketandtheBrazilbioethanolmarketinparticular...
(Date:11/24/2009)... The New York investment bank KTA Capital,s...greed an AU$6.7 mil convertible note private place...te placement was arranged by KTA Capital as Neuren... New York (PRWEB) November 23, 2...A Capital, LLC ("KTA Capital") has annou...
(Date:11/24/2009)... Health care employment grew by 29,000 jo...to show consistent growth during the U.S. recessio... in trouble, and health systems are coming closer ...ad of just administrators. , ...yment continued growing in October despite the she...
(Date:11/24/2009)...v.24/PRNewswire/--BlueMarbleEnergyCorp.announcedto...ority(OPDA)wererecentlyawarded$2millionbyWashingto...inaprivate/publicpartnershiptoconstructthestate,sf...,WA. ,, "Thisinvestmentwillsignificantlyspeedth...stoLincolnCounty,"saidBlueMarbleEnergyCEOKellyOgil...
Breaking Biology Technology:Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2
...d.,(TASE: ITGI) announced today the first commerci...ardium Covered Stent (PCS) in the UK, Over and Un... tissue,designed to set a barrier between the coro...ed for situations such as degenerated Saphenous Ve...first Over and Under(R) PCS commercial implantatio...
...affect patient response to ...2 Roche and DxS Ltd. have,signed an exclusive dis...Mutation Test and TheraScreen EGFR 29 Mutation Tes...her clinically relevant factors, to aid,doctors in...rom a specific,cancer therapy based on their mutat...
...s,area within SAFC(R), a member of the Sigma-Aldri...oduction of the OM700, a bubbler that offers,custo... precursor delivery,for larger lot sizes, enabling...creased safety controls., The OM700 offers reliab...tive organometallic precursors, such as trimethylg...
Other Biology Technology:Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability 2Roche Signs Exclusive Distribution Deal with DxS for K-RAS and EGFR Cancer Mutation Tests 2Roche Signs Exclusive Distribution Deal with DxS for K-RAS and EGFR Cancer Mutation Tests 3SAFC Hitech Introduces Large Scale Bubbler for Compound Semiconductor Production 2SAFC Hitech Introduces Large Scale Bubbler for Compound Semiconductor Production 3
(Date:11/26/2009)...t in eight European countries has shown that closi...andemic could have a significant role in reducing ...pen access journal BMC Infectious Diseases compa... weekends/holidays, finding that they were reduced...t and Antwerp University, Belgium, led a team of E...
(Date:11/25/2009)...produced in the stomach, may be used to boost resi... disease, Yale School of Medicine researchers repo...Journal of Neuroscience . , Parkinson,s disease ... an area of the midbrain known as the substantia n.... Reduced production of dopamine in late-stage Pa...
(Date:11/25/2009)...a lifetime, the heart pumps some 250 million liter...is, the muscle fibers of the heart have to be extr...lfgang Rottbauer, vice chair of the Department of ...airman: Prof. Dr. H. A. Katus), has discovered a p...e smallest muscular unit, the sarcomere. In cooper...
Breaking Biology News(10 mins):School closure could reduce swine flu transmission by 21 percent 2Hormone ghrelin can boost resistance to Parkinson's disease 2New genetic cause of cardiac failure discovered 2SYGNIS to Present at the 11th Rodman 26 Renshaw Annual Global Investment Conference 56338 1SYGNIS to Present at the 11th Rodman 26 Renshaw Annual Global Investment Conference 56338 2OAG Releases Prototype for Pandemic Disease Planning and Management 56336 1OAG Releases Prototype for Pandemic Disease Planning and Management 56336 2OAG Releases Prototype for Pandemic Disease Planning and Management 56336 3Restorative Therapies Inc Receives FDA Clearance for RT300 Enhancements 56333 1Restorative Therapies Inc Receives FDA Clearance for RT300 Enhancements 56333 2Restorative Therapies Inc Receives FDA Clearance for RT300 Enhancements 56333 3
... Department of Energys Office of Science today rel...publication, Facilities for the Future of Science:...made significant progress in deploying the scienti...tes needs to capture world scientific leadership, ...partments missions. , When it was published four ...
...One of the World,s Leading Software ..., Oct. 10 (OTC Bulletin,Board: CICI) Communicatio...lier of electronic signature solutions for busines... the recognized leader in biometric signature,veri...rd time in Software,Magazine,s Software 500 rankin...
...angladesh finds that folic acid supplements can dr...ls chronically exposed to arsenic-contaminated dri...aturally present in some soils and water. Arsenic...icant public health problem in at least 70 countri...o parts of the United States. Chronic arsenic exp...
Other Biology News:DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 2DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 3DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 4DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 5CIC Again Named to Software Magazine's Annual Prestigious Software 500 List 2CIC Again Named to Software Magazine's Annual Prestigious Software 500 List 3Folic acid lowers blood arsenic levels in Bangladesh 2Folic acid lowers blood arsenic levels in Bangladesh 3
Mouse Anti-Human XPC Polyclonal Antibody, Unconjugated from ABR-Affinity BioReagents
Rabbit Anti-Lck, phospho (Tyr192) Polyclonal Antibody, Unconjugated from Abcam
Anti-7H6 Antigen (tight-junction associated protein antigen) Monoclonal Antibody, Unconjugated, Clone 7H6 from Cell Sciences
Goat Anti-Ephrin B2 Polyclonal Antibody, Unconjugated from Abcam
Biology Products: